Mireille Tallandier Selected Research

odiparcil

1/2022	MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment.
1/2022	Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil.
1/2020	Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mireille Tallandier Research Topics

Disease

3	Mucopolysaccharidosis VI (Syndrome, Maroteaux-Lamy) 01/2022 - 01/2020
3	Lysosomal Storage Diseases (Lysosomal Storage Disease) 01/2022 - 01/2020
2	Mucopolysaccharidoses 01/2022 - 01/2020
1	Pain (Aches) 01/2022
1	Corneal Opacity 01/2022
1	Atherosclerosis 02/2006

Drug/Important Bio-Agent (IBA)

3	odiparcilIBA 01/2022 - 01/2020
3	GlycosaminoglycansIBA 01/2022 - 01/2020
1	ChondroitinIBA 01/2022
1	EnzymesIBA 01/2022
1	PPAR alphaIBA 02/2006
1	PPAR gammaIBA 02/2006

Therapy/Procedure

1	Therapeutics 01/2020